Qiagen (NYSE:QGEN) is making headlines with the launch and U.S. FDA clearance of its QIAstat-Dx Rise system, a move aimed at reshaping high-throughput molecular diagnostics for hospitals and labs. For investors, it is hard to ignore a product designed to automate testing processes, boost diagnostic speed, and cut down hands-on time. This combination speaks directly to growing demand for efficiency in healthcare settings. The fact that this is Qiagen’s third FDA-cleared syndromic testing product in 2025 points to an aggressive expansion of its portfolio and global reach, potentially raising expectations for the company’s future market position.
Looking at the stock, Qiagen has seen its share price climb nearly 4% so far this year and just over 4% in the past 12 months, even as five-year returns remain under water. Momentum appears to be picking up, with the stock rising around 2% in the last week and about 3% over the past three months. This may suggest markets are responding to recent developments, including this latest FDA clearance. While not every product launch moves the needle, Qiagen’s push to broaden its FDA-cleared offerings hints that the market may be starting to see greater upside in its growth story.
After a steady uptick in performance this year, investors may be weighing whether Qiagen is a value play with room to run, or if the market has already factored in its potential for future growth.
Advertisement
Most Popular Narrative: 9.2% Undervalued
According to the most widely followed narrative, Qiagen's current share price sits below its estimated fair value, indicating an undervalued opportunity based on future growth prospects and margins.
"The accelerated adoption of automation and digital workflows in both clinical and research settings, as seen with the development and imminent launch of three new high-throughput, digitally connected automated sample prep systems, positions Qiagen to address increasing throughput and efficiency needs, supporting both top-line growth and operating margin improvement in coming years."
What is really driving this bullish valuation call? There is a secret recipe of sales expansion and higher profit margins baked into the analysis, and it leans on a bold set of financial forecasts. Which numbers move the needle and just how much further could earnings soar? Find out how these projections shape the case for value well above today's price.
However, persistent weakness in life sciences funding and rising competition in diagnostics could quickly challenge this optimistic outlook for Qiagen’s future growth.
Taking a different approach, the SWS DCF model also weighs in on Qiagen’s value by using long-term cash flow projections instead of earnings multiples. This method suggests undervaluation as well, but whose assumptions are more realistic?
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Qiagen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Build Your Own Qiagen Narrative
If these views don’t match your own, or you want to dig deeper into the data and chart your own course, you can build a personalized take on Qiagen’s outlook in just a few minutes. Do it your way
Step up your investing game by checking out handpicked stocks set to make an impact right now. Don’t let high-potential opportunities slip past while you focus on just one company. Use these tailored ideas to help your portfolio reach the next level.
Tap into companies shaking up artificial intelligence in medicine by checking out breakthroughs using healthcare AI stocks.
Get ahead of the market with strong-yielding stocks. Seize the chance to spot dividend stocks with yields > 3% before others do.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Qiagen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.
